Primary UM diagnosis and therapies have also seen significant improvements in recent decades, and the recent approval of tebentafusp has increased life expectancy in HLA-A*02:01-positive patients with metastatic disease. This evidence concerns the gene HLA-A and metastatic neoplasm.